Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis
Public ClinicalTrials.gov record NCT05218096. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will evaluate the efficacy and safety of ALXN2050 (120 milligrams \[mg\], 180 mg) in participants with generalized myasthenia gravis (gMG). Safety will be monitored throughout the study.
Study identification
- NCT ID
- NCT05218096
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 70 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 130 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 27, 2022 (Actual)
- Primary completion
- Nov 30, 2023 (Actual)
- Completion
- Apr 3, 2024 (Actual)
- Last update posted
- Jan 9, 2025
2022 – 2024
United States locations
- U.S. sites
- 17
- U.S. states
- 12
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Phoenix | Arizona | 85028 | — |
| Research Site | Aurora | Colorado | 80045 | — |
| Research Site | Boca Raton | Florida | 33487 | — |
| Research Site | Port Charlotte | Florida | 33952 | — |
| Research Site | Tampa | Florida | 33612 | — |
| Research Site | Lexington | Kentucky | 40508 | — |
| Research Site | New Hyde Park | New York | 11042 | — |
| Research Site | Chapel Hill | North Carolina | 27514 | — |
| Research Site | Charlotte | North Carolina | 28207 | — |
| Research Site | West Chester | Ohio | 45069 | — |
| Research Site | Portland | Oregon | 97239 | — |
| Research Site | Springfield | Oregon | 97477 | — |
| Research Site | Philadelphia | Pennsylvania | 19104 | — |
| Research Site | Nashville | Tennessee | 37232 | — |
| Research Site | Houston | Texas | 77030 | — |
| Research Site | San Antonio | Texas | 78229 | — |
| Research Site | Milwaukee | Wisconsin | 53228 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 29 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05218096, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 9, 2025 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05218096 live on ClinicalTrials.gov.